Zefeng Xu — Endo Lab

article 2022

Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study

·doi:10.1002/hon.3026

Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…

2021

Early development and functional properties of tryptase/chymase double-positive mast cells from human pluripotent stem cells.

Journal of molecular cell biology ·doi:10.1093/jmcb/mjaa059

Mast cells (MCs) play a pivotal role in the hypersensitivity reaction by regulating the innate and adaptive immune responses. Humans have two types of MCs. The first type, termed MCTC, is found in the skin and other connective tissues and e…

article 2014

[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].

·doi:10.3760/cma.j.issn.0253-2727.2014.08.006

OBJECTIVE: To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. METHODS: A cohort of 58 PMF patients with anemia …